Cipla Limited

Overview

Cipla Limited is a listed pharmaceutical company based in Mumbai. Its businesses include prescription formulations, respiratory products, trade generics, consumer health and active pharmaceutical ingredients. The corporate identity is closely associated with access to medicines, but its operations involve a broad combination of research, regulatory work, manufacturing, distribution and commercial activity across markets. A therapeutic-area label describes a business focus, not a recommendation that a product is suitable for an individual. [1][9][10]

The company traces its incorporation and business origins to 1935. Its archive preserves the earlier name, Chemical Industrial & Pharmaceutical Laboratories, and records the founder Dr. K. A. Hamied. Contemporary leadership should be distinguished from that founding history: Achin Gupta became Managing Director and Global CEO from 1 April 2026, while Dr. Y. K. Hamied serves as Non-Executive Chairman. [2][5][4]

Company identity & key facts

The company’s legal identity, product brands and subsidiaries should be kept separate. A shareholder in Cipla Limited holds an interest in the listed issuer; a product purchase or laboratory enquiry may involve a particular operating entity or distribution channel. The exact counterparty is identified in the relevant financial, contract or product documentation. [6][11][12]

History & selected milestones

1. 1935The company is incorporated; Dr. K. A. Hamied establishes its founding business.
2. 1939The company archive records Mahatma Gandhi’s visit to Cipla.
3. 1960Dr. Y. K. Hamied joins the company after his chemistry research studies.
4. 1997The archive records the beginnings of the palliative-care initiative.
5. 1999The Cipla Generics business begins with a small team and three brands.
6. 2001The company records its offer of HIV triple therapy for less than one US dollar a day in Africa.
7. 2025Cipla marks nine decades of its history and announces the next executive succession.
8. 1 April 2026Achin Gupta succeeds Umang Vohra as MD and Global CEO.
9. 27 October 2026Q2 FY2026–27 consolidated results are announced under the new leadership.

These milestones describe selected changes in the business. The original records provide the fuller chronology. [2][10][1][5][7]

How the business makes money

Cipla’s formulation businesses sell finished medicines through different market structures. Branded prescription products, trade generics, institutional supply and consumer health reach customers through different channels. API sales serve other pharmaceutical businesses as well as supporting finished-product capabilities. A prescribing professional, a distributor, a hospital, a pharmacy and a patient occupy different positions in that commercial chain. [1][10][13]

Analytical context: pharmaceuticals require a sequence from development and regulatory submission through approval, launch, supply and demand. An application filing is not an approval; an approval is not yet a sales result. Pricing, product mix, competition and channel inventory can change revenue even where medical demand is stable. Manufacturing reliability, product quality and working capital determine whether the company can sustain delivery as well as report growth. [6][14]

Business activities & markets

Respiratory is a prominent Cipla capability, encompassing drug delivery through inhalation and associated product development. Such products combine the medicine and the delivery format, creating manufacturing and regulatory requirements beyond simply producing an oral tablet. Cipla’s broader prescription portfolio also includes areas such as anti-retroviral, urology, cardiovascular, anti-infective and central-nervous-system medicines. [9][1]

The Indian business combines branded prescription, trade generics and consumer health. Cipla Generics describes a distribution approach extending into smaller towns and remote markets, while Cipla Health presents consumer-facing brands. The distinctions concern commercial channels and operating businesses; they should not be collapsed into a single brand list or confused with separate listed issuers. [10][11]

North America, Africa, and emerging markets and Europe form further reporting views. These categories have their own competitive and regulatory conditions. Cipla Diagnostics adds a business around diagnostic products and solutions. A corporate directory can orient a reader to these activities, but specific product availability and regulatory status require the local operating company’s current documents. [1][12][8]

Brands, offerings & familiar names

A consumer brand can cover several formats or variants, each with its own ingredients, labelling and instructions. Product marketing claims are not adopted here as medical conclusions. This guide explains where names sit within the company’s business, while the applicable product information and qualified healthcare advice govern individual use. [11][14]

Group entities & reporting boundaries

Cipla publishes standalone and consolidated financial statements. Standalone reporting concerns the listed Indian company; consolidated reporting includes the relevant controlled entities and other interests under accounting rules. Geographic sales categories describe markets and can cross legal entities. A subsidiary, a distributor and a licensing partner have different relationships with the parent, even when each helps deliver a Cipla product. [6][8]

Cipla Health and other operating identities broaden the group’s commercial reach. Analytical context: buying a brand, acquiring a legal company, signing a distribution agreement and licensing a product create different assets, obligations and accounting effects. A business announcement should therefore be checked for the actual entity, territory, rights and completion conditions rather than interpreted solely from its headline. [11][6]

The company’s quarterly presentation combines its Indian prescription, generics and consumer-health activities within an India measure. Its African category includes South Africa. Adding the subcategory again to the regional total would double count it; the original table and footnotes show the intended structure. [7]

Leadership, ownership & governance

The current board directory identifies Dr. Y. K. Hamied as Non-Executive Chairman and Achin Gupta as MD and Global CEO. It identifies P. R. Ramesh as Vice Chairman and Lead Independent Director and Kamil Hamied as a Non-Executive Director. These roles should be used instead of assuming that older executive titles or family relationships remain unchanged. [4]

Achin Gupta’s succession was announced in October 2025 with an effective date of 1 April 2026; the current board directory confirms his serving role. The distinction between an announcement and the effective appointment date matters when writing a historical timeline. Governance responsibilities also extend beyond executives through committees, policies and oversight. [5][4]

Quarterly shareholding patterns provide promoter and public ownership at specified dates. Analytical context: family history explains continuity but is not a substitute for that legal shareholding record. Review the annual governance report, related-party disclosures and current filings for a fuller view of board oversight and public-shareholder interests. [15][6]

Corporate base, facilities & international reach

Cipla House in Lower Parel, Mumbai, is the registered and corporate address used in the reviewed disclosures. Its manufacturing and research activities are geographically distributed. The manufacturing page describes historical developments at Sikkim, Indore, Goa, Bommasandra in Bengaluru and Kurkumbh; some of that narrative explicitly refers to 2017–18, so it should not be treated as a current capacity statement. [1][13]

The company’s global market presence includes India, South Africa and North America alongside other regulated and emerging markets. A market can be served by local manufacturing, imported products, a subsidiary or a partner. It is therefore necessary to distinguish a country where sales occur from a country where the group owns a factory. [1][6]

Analytical context: facilities specialise by process, dosage form and regulatory authorisation. A site supplying one product or jurisdiction is not automatically approved for all others. Current annual reports and site-specific announcements are better evidence of a present facility boundary than an undated map or a historical commissioning article. [14][6]

Financial performance & dated figures

The table retains the company’s income-from-operations and EBITDA labels and the crore unit. These are quarterly consolidated results, not standalone accounts or full-year forecasts. Growth against the same quarter a year earlier and change against the immediately preceding quarter answer different questions. A release can describe sequential recovery while also reporting lower earnings year on year. [7]

Analytical context: a pharmaceutical business’s gross cash balances, net cash, borrowings and lease liabilities require careful definition. Some presentation cash measures include investments or deposits beyond bank cash. This profile does not convert a headline balance into an invented debt-free claim. The statutory balance sheet, cash-flow statement and notes provide the appropriate reconciliation. [8][6]

Research, access & portfolio direction

Cipla’s historical emphasis on access and its present interest in complex generics form complementary parts of the business story. The respiratory portfolio illustrates the combination of scientific development, delivery-device work and manufacturing capability. The generics business emphasises distribution reach, while consumer health brings products into a different customer channel. Those approaches create different demands on research, regulation and commercial organisation. [9][10][11]

Analytical context: access to medicines depends on price, availability, procurement, health systems and appropriate use, not merely on a product’s existence. A corporate access programme or historical price offer can be significant without proving universal availability. Similarly, a complex-product pipeline has commercial potential but requires successful approvals and launches. Corporate strategy should be evaluated through dated milestones and outcomes rather than a promise that every research programme will succeed. [1][6]

People, skills & quality culture

The company’s careers pages describe work across research, manufacturing, commercial functions and support teams, with learning initiatives including Cipla University. A pharmaceutical workforce includes scientific, technical and operational skills as well as sales capability. Job descriptions and current recruitment notices are more precise evidence of hiring needs than assuming that every business expansion implies the same type or location of employment. [16]

Cipla’s quality page describes vendor audits, development quality assurance, manufacturing controls, complaint handling and pharmacovigilance. Analytical context: these functions form a chain. Good development records support technology transfer, controlled production supports batch release, and post-market information can reveal issues requiring investigation. A company’s quality-system description explains its intended controls; facility-specific regulatory records are still needed to assess inspection status. [14]

Sustainability, community & palliative care

The company presents sustainability through environmental, community, governance and access-related themes. The relevant reports should be checked for the year, legal boundary, baseline and assurance scope of a metric. Energy use at a factory, global workforce totals and the reach of a community programme are different categories of evidence and should not be combined into a single undated claim. [17][6]

Cipla Foundation describes community partnerships and efforts to improve access to essential care for underserved groups. Palliative care has a distinct place in the company’s social history and dedicated programme. Analytical context: palliative care addresses the needs of people and families facing serious illness; a corporate profile can explain the institution without substituting for clinical guidance. Programme expenditure and participant numbers should also be distinguished from measured long-term outcomes. [18][19][2]

Key developments to 3 November 2026

The principal leadership change is Achin Gupta’s appointment from 1 April 2026. The September-quarter results released on 27 October provide a dated financial and operating snapshot under that leadership. The company’s current filings should be used for subsequent changes to board composition, share capital, product approvals or agreements. [5][4][7]

Analytical context: a product announcement should be described at its actual stage—application, approval, launch, agreement or completed transaction. Country rights and manufacturing sites can matter as much as the product name. This profile preserves a clear trail to the quarterly archive and annual report so that future updates can revise the particular fact that changed without rewriting history as though every development occurred at once. [8][6]

Business risks & regulatory context

Analytical context: generic price erosion, launch timing, competition, procurement decisions, currency movements and supply continuity can affect results. Complex respiratory and other specialised products add development and regulatory execution requirements. Manufacturing observations, recalls, import restrictions, litigation and intellectual-property matters need individual analysis by product, facility and jurisdiction. These are risk categories, not an assertion that a particular unresolved action exists today. [6][14]

Inspection observations and final regulatory conclusions should not be treated as synonyms. Any update about them must retain the regulator, facility, date and status. The quality page is a description of internal systems rather than proof of a universal regulatory clearance. This encyclopedia provides business and historical context; it does not offer treatment instructions, live share pricing or a recommendation to buy the company’s securities. [14][8]

Frequently asked questions

A plain-language business glossary

Formulation

A finished medicine supplied in a particular dosage form.

API

Active pharmaceutical ingredient used in making finished medicines.

Trade generics

A distribution and commercial approach for generic medicines, distinct from an individual product approval route.

Inhalation delivery

Delivery of a medicine through an inhaled dosage form or device.

Pharmacovigilance

Collecting, assessing and responding to information about medicine safety.

cGMP

Current good manufacturing practice: applicable production and quality requirements.

PAT

Profit after tax; different from operating profit or cash generated.

Reporting perimeter

The legal entities and activities included in a particular set of financial statements.

Reports & research documents

Use financial statements for accounting figures, annual reports for the wider business and governance picture, and dated announcements for subsequent developments. Figures with different reporting boundaries or periods should be compared only after checking their definitions.

Sources, review date & editorial scope

Reviewed: 3 November 2026. This profile combines original explanations with the linked official company publications and regulatory filings. Financial tables retain their currency, period and reporting basis. Company targets, forecasts and product claims are attributed to their issuer.

Products, entities, locations and developments are selected for orientation. The linked disclosures contain fuller subsidiary registers, accounting notes, governance reports and risk information. A later filing may change a fact recorded here. Historical announcements are dated so they are not mistaken for current appointments or completed transactions.

1. Company overview and identity ↗Cipla Limited · reviewed 3 Nov 2026
2. Cipla archives and original corporate name ↗Cipla Limited · reviewed 3 Nov 2026
3. MCA record of companies registered before 1980 ↗Cipla Limited · reviewed 3 Nov 2026
4. Current board of directors ↗Cipla Limited · reviewed 3 Nov 2026
5. Achin Gupta succession announcement ↗Cipla Limited · reviewed 3 Nov 2026
6. Annual report FY2025–26 ↗Cipla Limited · reviewed 3 Nov 2026
7. Q2 FY2026–27 press release, 27 October 2026 ↗Cipla Limited · reviewed 3 Nov 2026
8. Quarterly results and statutory filings ↗Cipla Limited · reviewed 3 Nov 2026
9. Respiratory portfolio and delivery systems ↗Cipla Limited · reviewed 3 Nov 2026
10. Cipla Generics business ↗Cipla Limited · reviewed 3 Nov 2026
11. Cipla Health and consumer brands ↗Cipla Limited · reviewed 3 Nov 2026
12. Cipla Diagnostics ↗Cipla Limited · reviewed 3 Nov 2026
13. Manufacturing capabilities and historical site developments ↗Cipla Limited · reviewed 3 Nov 2026
14. Quality management and pharmacovigilance ↗Cipla Limited · reviewed 3 Nov 2026
15. Quarterly shareholding patterns ↗Cipla Limited · reviewed 3 Nov 2026
16. Careers and learning programmes ↗Cipla Limited · reviewed 3 Nov 2026
17. Sustainability approach ↗Cipla Limited · reviewed 3 Nov 2026
18. Cipla Foundation and community programmes ↗Cipla Limited · reviewed 3 Nov 2026
19. Cipla Palliative Care ↗Cipla Limited · reviewed 3 Nov 2026